Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Tiragolumab?
Tiragolumab is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Esophageal Squamous Cell Carcinoma (ESCC)....
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According...
Tiragolumab by Genentech USA for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Tiragolumab by Genentech USA for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...